MELANIE LEHMAN: Open Payments
NPI 1659478360 · AUBURN, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$858 in 44 payments from 10 companies in 2025. Trend: 2023 $679 · 2024 $1,103 · 2025 $858
Food & beverage: $758Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $373 |
| Janssen Biotech, Inc. | 2 | $114 |
| Novartis Pharmaceuticals Corporation | 5 | $84 |
| Regeneron Healthcare Solutions, Inc. | 3 | $74 |
| Incyte Corporation | 1 | $62 |
| Lilly USA, LLC | 3 | $57 |
| Galderma Laboratories, L.P. | 2 | $31 |
| GENZYME CORPORATION | 1 | $26 |
| UCB, Inc. | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: SKYRIZI, TREMFYA, DUPIXENT, COSENTYX, Opzelura, TALTZ, RINVOQ, NEMLUVIO.
Industry payments across CA — which companies pay providers there.
